Please wait...
| ID | PMID | YEAR | Sequence | MAP | Name | C-ter MOD | N-ter MOD | Linear/Cyclic | Stereo-Chemistry | Modified | Length | Fuction | Activity | RBCs Source | Origin | Experimental structure | Non-Hemolytic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19799950 | 2010 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | SK84 | Free | Free | Linear | L | None | 84 | Antimicrobial and Anticancer | 0.01% hemolysis at 100μM | Mouse | SK84 (larvae of Drosophila virilis) | NA | NA | ||
| 19799950 | 2010 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | SK84 | Free | Free | Linear | L | None | 84 | Antimicrobial and Anticancer | 0.01% hemolysis at 100μM | Human | SK84 (larvae of Drosophila virilis) | NA | NA | ||
| 21928440 | 2011 | CGETCVGGTCNTPGCTCSWPVCTRNGLPV{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 29 | Anticancer and Anti-HIV | IC50 = 26 µM | Human | Kalata (Oldenlandia affinis) | NA | NA | ||
| 21928440 | 2011 | C{d}G{d}E{d}T{d}C{d}V{d}G{d}G{d}T{d}C{d}N{d}T{d}P{d}G{d}C{d}T{d}C{d}S{d}W{d}P{d}V{d}C{d}T{d}R{d}N{d}G{d}L{d}N{d}P{d}V{d}{cyc:N-C} | D-Kalata B1 | Free | Free | Cyclic | D | None | 29 | Anticancer and Anti-HIV | IC50 = 77 µM | Human | Kalata analog (Oldenlandia affinis) | NA | NA | ||
| 14514057 | 2003 | KWKLFKKIGIGKFLHSAKKF{ct:Amid} | CA-MA | Amidation | Free | Linear | L | None | 20 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14514057 | 2003 | KWKKLLKKPLLKKLLKKL{ct:Amid} | CA-MA analogue P5 | Amidation | Free | Linear | L | None | 18 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14514057 | 2003 | KWKLKPLLKKLLKKL{ct:Amid} | P6 | Amidation | Free | Linear | L | None | 15 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14514057 | 2003 | KWKKLLKKPLKLKL{ct:Amid} | P7 | Amidation | Free | Linear | L | None | 14 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14514057 | 2003 | KPLLKKLLKKL{ct:Amid} | P8 | Amidation | Free | Linear | L | None | 11 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14514057 | 2003 | KLLKKPLKLKL{ct:Amid} | P9 | Amidation | Free | Linear | L | None | 11 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVFKRLEKLFSKIQNWK | Anal 1 | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal and Anticancer | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) analogs (Helicobacter pylori) | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVFKRLEKLFSKIWNDK | Anal 2 | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal and Anticancer | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) analogs (Helicobacter pylori) | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVFKRLEKLFSKIWNWK | Anal 3 | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal and Anticancer | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) analogs (Helicobacter pylori) | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVFKRLEKSFSKIQNDK | Anal 4 | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal and Anticancer | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) analogs (Helicobacter pylori) | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVSKRLEKLFSKIQNDK | Anal 5 | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal and Anticancer | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) analogs (Helicobacter pylori) | NA | Non-hemolytic | ||
| 10973820 | 2000 | ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE | CRAMP | Free | Free | Linear | L | None | 38 | Antimicrobial and Anticancer | 2.2% hemolytic at 100μM | Human | Derived from CRMAP, a member of cathelicidin-derived antimicrobial peptides | NA | NA | ||
| 10973820 | 2000 | GEKLKKIGQKIKNFFQKL | CRAMP-18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Anticancer | 0% hemolytic at 100μM (non-hemolytic) | Human | CRMAP | NA | Non-hemolytic | ||
| 10973820 | 2000 | GKKLKKIGQKIKNFFQKL | K2-CRAMP-18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Anticancer | 0% hemolytic at 100μM (non-hemolytic) | Human | CRMAP-18 analogs | NA | Non-hemolytic | ||
| 10973820 | 2000 | GEKLKKIGKKIKNFFQKL | K9-CRAMP-18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Anticancer | 0% hemolytic at 100μM (non-hemolytic) | Human | CRMAP-18 analogs | NA | Non-hemolytic | ||
| 10973820 | 2000 | GEKLKKIGQKIKKFFQKL | K13-CRAMP-18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Anticancer | 0% hemolytic at 100μM (non-hemolytic) | Human | CRMAP-18 analogs | NA | Non-hemolytic | ||
| 10973820 | 2000 | GEKLKKIGQKIKNFFKKL | K16-CRAMP-18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Anticancer | 0.2% hemolytic at 100μM | Human | CRMAP-18 analogs | NA | NA | ||
| 23609760 | 2013 | FVDLKKIANIINSIFGK | Temporin-1CEa | Free | Free | Linear | L | None | 17 | Antimicrobial, Anticancer and moderate Hemolytic | LC50 =95.7μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23609760 | 2013 | FVDLKKIANIINSIFKK | LK1 | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =1,467μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23609760 | 2013 | FKDLKKIANIINSIFKK | LK2(5) | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =1,186μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23609760 | 2013 | FVKLKKIANIINSIFKK | LK2(6) | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =1,993μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23609760 | 2013 | FKKLKKIANIINSIFKK | LK3 | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =4,649μM | Human | Defencin | NA | NA | ||
| 23609760 | 2013 | FVKLKKILNIINSIFKK | LK2(6)A(L) | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =86.99μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23609760 | 2013 | FVKLKKILNIILSIFKK | LK2(6)AN(2L) | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =28.34μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}W{d}L{d}L{d}A{d}L{d}K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}{ct:Amid} | D-LAK120 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 4.06±1.30μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}W{d}L{d}P{d}A{d}L{d}K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}{ct:Amid} | D-LAK120-P13 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 11.66±0.03μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}W{d}L{d}A{d}L{d}A{d}K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-LAK120-A | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 17.42±2.17μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}W{d}L{d}P{d}L{d}A{d}K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-LAK120-AP13 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 58.61±10.41μMc | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}L{d}A{d}L{d}H{d}A{d}L{d}K{d}K{d}W{d}L{d}H{d}A{d}L{d}K{d}K{d}L{d}A{d}H{d}L{d}A{d}L{d}K{d}K{d}{ct:Amid} | D-LAK120-H | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 20.29±2.42μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}A{d}L{d}A{d}H{d}A{d}L{d}K{d}K{d}W{d}L{d}P{d}A{d}L{d}K{d}K{d}L{d}A{d}H{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-LAK120-HP13 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 79.61±2.80μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}A{d}L{d}A{d}K{d}A{d}L{d}K{d}H{d}W{d}L{d}P{d}A{d}L{d}H{d}K{d}L{d}A{d}K{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-LAK80-HP13 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 8.61±0.35μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}A{d}L{d}K{d}H{d}A{d}L{d}A{d}K{d}W{d}L{d}P{d}A{d}L{d}K{d}A{d}L{d}A{d}H{d}K{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-LAK160-HP13 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 185.0±18.65μM | Human | Synthetic peptide | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | P | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 5.20 ± 0.02μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLK{d}TFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | K7D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 10.4 ± 0.04μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSLKK{d}TVLHTLLKAISS{nt:Acet}{ct:Amid} | K14D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 5.20 ± 0.02μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSLKKTVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 20.81 ± 0.10 μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLK{d}TFKSLKK{d}TVLHTLLKAISS{nt:Acet}{ct:Amid} | K7D/K14 D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 20.81 ± 0.15μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K14D/K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 20.81 ± 0.06μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLK{d}TFKSLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K7D/K14D/K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 81.31 ± 0.17μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K7D/K10D/K14D/K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 325.20 ± 0.82μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWK{d}SFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K3D/K7D/K10D/K14D/K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC >325.20μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | K{d}WK{d}SFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K1D/K3D/K7D/K10D/K14D/K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC >325.20μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFL{d}KTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | L6D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =10.40 ± 0.08μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSL{d}KKTVLHTLLKAISS{nt:Acet}{ct:Amid} | L12D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =20.81 ± 0.03μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSLKKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L20D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =20.81 ± 0.13μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFL{d}KTFKSL{d}KKTVLHTLLKAISS{nt:Acet}{ct:Amid} | L6D/L12D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =20.81 ± 0.10 μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L12D/L20D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =81.31 ± 0.43μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFL{d}KTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L6D/L12D/L20D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =162.61 ± 0.19μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFL{d}KTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L6D/L12D/L17D/L20D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =81.31 ± 1.05μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFL{d}KTFKSL{d}KKTVLHTL{d}L{d}KAISS{nt:Acet}{ct:Amid} | L6D/L12D/L17D/L20D/L21D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC >325.20μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 21729875 | 2011 | GKGRWLERIGKAGGIIIGGALDHL{ct:Amid} | NRC-01 | Amidation | Free | Linear | L | None | 24 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | WLRRIGKGVKIIGGAALDHL{ct:Amid} | NRC-02 | Amidation | Free | Linear | L | None | 20 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GRRKRKWLRRIGKGVKIIGGAALDHL{ct:Amid} | NRC-03 | Amidation | Free | Linear | L | None | 26 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | NRC-04 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | FLGALIKGAIHGGRFIHGMIQNHH{ct:Amid} | NRC-05 | Amidation | Free | Linear | L | None | 24 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWGSIFKHGRHAAKHIGHAAVNHYL{ct:Amid} | NRC-06 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | RWGKWFKKATHVGKHVGKAALTAYL{ct:Amid} | NRC-07 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | RSTEDIIKSISGGGFLNAMNA{ct:Amid} | NRC-08 | Amidation | Free | Linear | L | None | 21 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | FFRLLFHGVHHGGGYLNAA{ct:Amid} | NRC-09 | Amidation | Free | Linear | L | None | 19 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | FFRLLFHGVHHVGKIKPRA{ct:Amid} | NRC-10 | Amidation | Free | Linear | L | None | 19 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKSVFRKAKKVGKTVGGLALDHYL{ct:Amid} | NRC-11 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKKWFNRAKKVGKTVGGLAVDHYL{ct:Amid} | NRC-12 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWRTLLKKAEVKTVGKLALKHYL{ct:Amid} | NRC-13 | Amidation | Free | Linear | L | None | 23 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | AGWGSIFKHIFKAGKFIHGAIQAHND{ct:Amid} | NRC-14 | Amidation | Free | Linear | L | None | 26 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GFWGKLFKLGLHGIGLLHLHL{ct:Amid} | NRC-15 | Amidation | Free | Linear | L | None | 21 | Anticancer | 50% hemolytic at 64μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKKWLRKGAKHLGQAAIK{ct:Amid} | NRC-16 | Amidation | Free | Linear | L | None | 19 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKKWLRKGAKHLGQAAIKGLAS | NRC-17 | Free | Free | Linear | L | None | 23 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKKWFTKGERLSQRHFA | NRC-18 | Free | Free | Linear | L | None | 18 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | FLGLLFHGVHHVGKWIHGLIHGHH{ct:Amid} | NRC-19 | Amidation | Free | Linear | L | None | 24 | Anticancer | 50% hemolytic at 16μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GFLGILFHGVHHGRKKALHMNSERRS | NRC-20 | Free | Free | Linear | L | None | 26 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKDWFRKAKKVGKTVGGLALNHYL{ct:Amid} | NRC-123 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GIRKWFKKAAHVGKEVGKVALNACL | NRC-124 | Free | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GLKKWFKKAVHVGKKVGKVALNAYL{ct:Amid} | NRC-125 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWRKWIKKATHVGKHIGKAALDAYI{ct:Amid} | NRC-126 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GCKKWFKKAAHVGKNVGKVALNAYL{ct:Amid} | NRC-127 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GIRKWFKKAAHVGKKVGKVALNAYL{ct:Amid} | NRC-128 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GR{d}R{d}K{d}R{d}K{d}WLR{d}R{d}IGK{d}GVK{d}IIGGAALDHL{ct:Amid} | NRC-03D | Amidation | Free | Linear | Mix | None | 26 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GRRKRKWLRRIGKGVKIIGGAALDHL{nt:Biotin}{ct:Amid} | NRC-03B | Amidation | Biotin | Linear | L | None | 26 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GIGKFLHSAKKFGKAFVGEIMNS{ct:Amid} | Mag2 | Amidation | Free | Linear | L | None | 23 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Magainin-2 | NA | NA | ||
| 21955251 | 2011 | GIIKKI{ct:Amid} | G(IIKK)I | Amidation | Free | Linear | L | None | 6 | Antimicrobial and Antitumor | Non-hemolytic up to 250 μM | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 21955251 | 2011 | GIIKKIIKKI{ct:Amid} | G(IIKK)2I | Amidation | Free | Linear | L | None | 10 | Antimicrobial and Antitumor | Non-hemolytic up to 250 μM | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 21955251 | 2011 | GIIKKIIKKIIKKI{ct:Amid} | G(IIKK)3I | Amidation | Free | Linear | L | None | 14 | Antimicrobial and Antitumor | EC50 >250μM | Human | Synthetic peptides | NA | NA | ||
| 21955251 | 2011 | GIIKKIIKKIIKKIIKKI{ct:Amid} | G(IIKK)4I | Amidation | Free | Linear | L | None | 18 | Antimicrobial and Antitumor | EC50 = 41±2μM | Human | Synthetic peptides | NA | NA | ||
| 23328867 | 2013 | THRPPMWSPVWPGGGKLL{d}LKL{d}LK{d}K{d}LLKL{d}LKKK | TfR-lytic hybrid peptide | Free | Free | Linear | Mix | None | 32 | Anticancer | 17% hemolysis at 100μM | Mouse | Synthetic peptide | NA | NA | ||
| 24185042 | 2013 | IKLSPETKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | Hymenochirin-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 213 ± 18 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | LKIPGFVKDTLKKVAKGIFSAVAGAMTPS | Hymenochirin-2B | Free | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 210 ± 21 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKIPAVVKDTLKKVAKGVLSAVAGALTQ | Hymenochirin-3B | Free | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at >400 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKIPAFVKDTLKKVAKGVISAVAGALTQ | Hymenochirin-4B | Free | Free | Linear | L | None | 28 | Antitumor | 50 % Hemolysis at 158 ± 6 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSKETKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [P5K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 205 ± 15 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPKTKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [E6K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 186 ± 4 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPETKKNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [D9K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 174 ± 12 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSKKTKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [P5K,E6K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 137 ± 11 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSKETKKNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [P5K,D9K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 127 ± 9 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPKTKKNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [E6K,D9K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 85 ± 5 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPK{d}TKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [E6k]-1B | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 29 | Antitumor | 50 % Hemolysis at 188 ± 8 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPETKK{d}NLKKVLKGAIKGAIAVAKMV{ct:Amid} | [D9k]-1B | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 29 | Antitumor | 50 % Hemolysis at >400 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPK{d}TKK{d}NLKKVLKGAIKGAIAVAKMV{ct:Amid} | [E6k,D9k]-1B | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 29 | Antitumor | 50 % Hemolysis at 302 ± 21 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 25123187 | 2014 | KWKSFLKTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | P(PNW) | Amidation | Acetylation | Linear | L | None | 26 | Anticancer | MHC % Hemolysis at 10.41 ± 0.02 µM | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 25123187 | 2014 | KIKSFLKTFKSWKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | PMW | Amidation | Acetylation | Linear | L | None | 26 | Anticancer | MHC % Hemolysis at 10.41 ± 0.01 µM | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 25123187 | 2014 | KIKSFLKTFKSLKKTVLHTLLKAWSS{nt:Acet}{ct:Amid} | PCW | Amidation | Acetylation | Linear | L | None | 26 | Anticancer | MHC % Hemolysis at 10.41 ± 0.01 µM | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 25241629 | 2014 | LKLSPKTKDTLKKVLKGAIKGAIAIASMA{ct:Amid} | Hymenochirin-1Pa | Amidation | Free | Linear | L | None | 29 | Antimicrobial, Antitumor | 50 % Hemolysis at 162 ± 13 µM | Human | Skin Secretions Ofthe Frog Pseudhymenochirus Merlini | α-Helix | NA | ||
| 25241629 | 2014 | LKLSPKTKKTLKKVLKGAIKGAIAIASMA{ct:Amid} | [D9K]Hymenochirin-1Pa | Amidation | Free | Linear | L | None | 29 | Antimicrobial, Antitumor | 50 % Hemolysis at 192 ± 21 µM | Human | Analog Of Hymenochirin-1Pa, Skin Secretions Ofthe Frog Pseudhymenochirus Merlini | α-Helix | NA | ||
| 25241629 | 2014 | LKLSPKTKK{d}TLKKVLKGAIKGAIAIASMA{ct:Amid} | [D9k]Hymenochirin-1Pa | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 29 | Antimicrobial, Antitumor | 50 % Hemolysis at >400 µM | Human | Analog Of Hymenochirin-1Pa, Skin Secretions Ofthe Frog Pseudhymenochirus Merlini | α-Helix | NA | ||
| 25447194 | 2014 | IKIPSFFRNILKKVGKEAVSLIAGALKQS | Pseudhymenochirin-1Pb(Ps-1Pb) | Free | Free | Linear | L | None | 29 | Antimicrobial, Antitumor | 50 % Hemolysis at 28 ± 2 µM | Human | Skin Secretions Of The Frog Pseudhymenochirus Merlini | α-Helix | NA | ||
| 25447194 | 2014 | GIFPIFAKLLGKVIKVASSLISKGRTE | (Pseudhymenochirin-2Pa)Ps-2Pa | Free | Free | Linear | L | None | 27 | Antimicrobial, Antitumor | 50 % Hemolysis at 6.2 ± 1.0 µM | Human | Skin Secretions Of The Frog Pseudhymenochirus Merlini | α-Helix | NA | ||
| 26204061 | 2015 | GIIKKIIKKIIKKI{ct:Amid} | FITC | Amidation | Free | Linear | L | None | 14 | Antibacterial and Anticancer | 50 % Hemolysis at 256 µM | Human | Synthetic Amphiphiles | α-Helix | Low hemolytic | ||
| 26204061 | 2015 | IIKKIIKKIIKKI{ct:Amid} | 1 | Amidation | Free | Linear | L | None | 13 | Antibacterial and Anticancer | 50 % Hemolysis at 256 µM | Human | Synthetic Amphiphiles | α-Helix | Low hemolytic | ||
| 26204061 | 2015 | GIIKKIIKKIIKK{ct:Amid} | 2 | Amidation | Free | Linear | L | None | 13 | Antibacterial and Anticancer | 50 % Hemolysis at 500 µM | Human | Synthetic Amphiphiles | α-Helix | Low hemolytic | ||
| 26204061 | 2015 | IIKKIIKKIIKK{ct:Amid} | Rhodamine | Amidation | Free | Linear | L | None | 12 | Antibacterial and Anticancer | 50 % Hemolysis at >1000 µM | Human | Synthetic Amphiphiles | α-Helix | Low hemolytic | ||
| 26100634 | 2015 | GLFGVLAKVAAHVVPAIAEHF{ct:Amid} | Maculatin 1.1 | Amidation | Free | Linear | L | None | 21 | Anticancer, Antibacterial Gram- | 50 % Hemolysis at 29.5 ± 1.0 µM | Human | Australian Tree Frog Litoria Genimaculata | α-Helical | NA | ||
| 26100634 | 2015 | GIGAVLKVTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Anticancer, Antibacterial Gram- | 50 % Hemolysis at 1.2± 0.1 µM | Human | Bee Venom | α-Helical | NA | ||
| 25839356 | 2015 | FIHHIIGWISHGVRAIHRAIH{ct:Amid} | Gad-1 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 100 % Hemolysis at 100 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FIHHIIGWISHGVRAIHRAIH{ct:Amid} | Gad-1 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 100 % Hemolysis at 200 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FIHHIIGWISHGVRAIHRAIH{ct:Amid} | Gad-1 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 100 % Hemolysis at 400 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FLHHIVGLIHHGLSLFGDR{ct:Amid} | Gad-2 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 50 % Hemolysis at 56 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FLHHIVGLIHHGLSLFGDR{ct:Amid} | Gad-2 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | <90 % Hemolysis at 100 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FLHHIVGLIHHGLSLFGDR{ct:Amid} | Gad-2 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 100 % Hemolysis at 200 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FLHHIVGLIHHGLSLFGDR{ct:Amid} | Gad-2 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 100 % Hemolysis at 400 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25462264 | 2015 | VKRFKKFFRKLKKSV{ct:Amid} | B1 | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | Derivative Of Cathelicidin-Bf15 (Bf-15) | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKAV{ct:Amid} | B1-Ala | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKVV{ct:Amid} | B1-Val | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKLV{ct:Amid} | B1-Leu | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKFV{ct:Amid} | B1-Phe | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKGV{ct:Amid} | B1-Gly | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKQV{ct:Amid} | B1-Gln | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKTV{ct:Amid} | B1-Thr | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKKV{ct:Amid} | B1-Lys | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKRV{ct:Amid} | B1-Arg | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKHV{ct:Amid} | B1-His | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | <10 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKDV{ct:Amid} | B1-Asp | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 25462264 | 2015 | VKRFKKFFRKLKKEV{ct:Amid} | B1-Glu | Amidation | Free | Linear | L | None | 15 | Anticancer, Anti-migratory | 5 % Hemolysis at 160 µM | Rabbit | B1 Analog | α-Helical | Low hemolytic | ||
| 27187467 | 2016 | GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ{ct:Amid} | Dermaseptin-PD-1 | Amidation | Free | Linear | L | None | 30 | Antibacterial, Antifungal, Anticancer | 100 % Hemolysis at >156.8 µM | Horse | Pachymedusa Dacnicolor | α-Helix | Low hemolytic | ||
| 27187467 | 2016 | GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI{ct:Amid} | Dermaseptin-PD-2 | Amidation | Free | Linear | L | None | 32 | Antibacterial, Antifungal, Anticancer | 100 % Hemolysis at >161.6 µM | Horse | Pachymedusa Dacnicolor | α-Helix | Low hemolytic | ||
| 27129462 | 2016 | RGSALTHLP | RP9 | Free | Free | Linear | L | None | 9 | Antibacterial, Anticancer | 3.3 ± 0.5 % Hemolysis at 61.2 µM | Human | Crocodile Leukocyte Extract | α-Helix | NA | ||
| 27129462 | 2016 | RGSALTHLP | RP9 | Free | Free | Linear | L | None | 9 | Antibacterial, Anticancer | 5.7 ± 0.2 % Hemolysis at 122.4 µM | Human | Crocodile Leukocyte Extract | α-Helix | NA | ||
| 27197902 | 2016 | GLRRALLRLLRSLRRLLLRA | P7 | Free | Free | Linear | L | None | 20 | Antibacterial, Antitumor, Antifungal | 0 % Hemolysis at 4-32 µM | Mouse | Cell-Penetrating Peptide Pptg20 | α-Helix | Non-hemolytic | ||
| 26952034 | 2016 | ASKAGAIAGKIAKVALKAL | XLAsp-P1 | Free | Free | Linear | L | None | 19 | Antibacterial, Anticancer | 0 % Hemolysis at 8 µg/mL | Rabbit | Skin Of Xenopus Laevis | α-Helix | Low hemolytic | ||
| 26952034 | 2016 | ASKAGAIAGKIAKVALKAL | XLAsp-P2 | Free | Free | Linear | L | None | 19 | Antibacterial, Anticancer | 0 % Hemolysis at 16 µg/mL | Rabbit | Skin Of Xenopus Laevis | α-Helix | Low hemolytic | ||
| 26952034 | 2016 | ASKAGAIAGKIAKVALKAL | XLAsp-P3 | Free | Free | Linear | L | None | 19 | Antibacterial, Anticancer | 0 % Hemolysis at 32 µg/mL | Rabbit | Skin Of Xenopus Laevis | α-Helix | Low hemolytic | ||
| 26952034 | 2016 | ASKAGAIAGKIAKVALKAL | XLAsp-P4 | Free | Free | Linear | L | None | 19 | Antibacterial, Anticancer | 6.4 % Hemolysis at 64 µg/mL | Rabbit | Skin Of Xenopus Laevis | α-Helix | Low hemolytic | ||
| 26952034 | 2016 | ASKAGAIAGKIAKVALKAL | XLAsp-P5 | Free | Free | Linear | L | None | 19 | Antibacterial, Anticancer | <20 % Hemolysis at 128 µg/mL | Rabbit | Skin Of Xenopus Laevis | α-Helix | Low hemolytic | ||
| 27907988 | 2016 | KRIVQRIKDFLR{ct:Amid} | KR12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antitumor | 30 % Hemolysis at 0.78 µg/mL | Rabbit | Cathelicidin Ll-37 | α-Helix | NA | ||
| 27907988 | 2016 | KRIVQRIKDFLR{ct:Amid} | KR12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antitumor | <45 % Hemolysis at 7.8 µg/mL | Rabbit | Cathelicidin Ll-37 | α-Helix | NA | ||
| 27907988 | 2016 | KRIVQRIKDFLR{ct:Amid} | KR12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antitumor | <45 % Hemolysis at 15.6 µg/mL | Rabbit | Cathelicidin Ll-37 | α-Helix | NA | ||
| 27907988 | 2016 | KRIVQRIKDFLR{ct:Amid} | KR12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antitumor | 70 % Hemolysis at 31.2 µg/mL | Rabbit | Cathelicidin Ll-37 | α-Helix | NA | ||
| 27907988 | 2016 | KRIVQRIKDFLR{ct:Amid} | KR12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antitumor | 70 % Hemolysis at 62.5 µg/mL | Rabbit | Cathelicidin Ll-37 | α-Helix | NA | ||
| 27907988 | 2016 | KRIVQRIKDFLR{ct:Amid} | KR12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antitumor | 73 % Hemolysis at 125 µg/mL | Rabbit | Cathelicidin Ll-37 | α-Helix | NA | ||
| 27809507 | 2016 | PSPCGESCVFIPCISALIGCSCKNKVCYR | parigidin-br3 | Free | Free | Linear | L | None | 29 | cytotoxic, Anticancer | ~13-20 % Hemolysis at 21-42 µM | Human | Plant Palicourea Rigida | α-Helix/β-Sheet | NA | ||
| 26949161 | 2016 | AEAEARARAEAEARAR{nt:Acet}{ct:Amid} | EAR16-II | Amidation | Acetylation | Linear | L | None | 16 | Anticancer | <5 % Hemolysis at 1.25-125 µg/mL | Rabbit | Complementary Peptide Eak16-Ii | α-Helix; β-Strand | Non-hemolytic | ||
| 26949161 | 2016 | AEAEARAR{nt:Acet}{ct:Amid} | EAR8-II | Amidation | Acetylation | Linear | L | None | 8 | Anticancer | <5 % Hemolysis at 1.25-125 µg/mL | Rabbit | Complementary Peptide Eak16-Ii | α-Helix; Random coil | Non-hemolytic | ||
| 26949161 | 2016 | AAEEAARR{nt:Acet}{ct:Amid} | EAR8-IIa | Amidation | Acetylation | Linear | L | None | 8 | Anticancer | <5 % Hemolysis at 1.25-125 µg/mL | Rabbit | Complementary Peptide Eak16-Ii | α-Helix; Random coil | Non-hemolytic | ||
| 26949161 | 2016 | LLEELLRR{nt:Acet}{ct:Amid} | ELR8-IIa | Amidation | Acetylation | Linear | L | None | 8 | Anticancer | <5 % Hemolysis at 1.25-125 µg/mL | Rabbit | Complementary Peptide Eak16-Ii | α-Helix; Random coil | Non-hemolytic | ||
| 28165293 | 2017 | FKCRRWQWRMKKLGAPSITCVRRAF{cyc:N-C} | LFcinB | Free | Free | Cyclic | L | None | 25 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Lf (Blf) | β-Hairpin | NA | ||
| 28165293 | 2017 | FK{nnr:*}RRWQWRMKKLGAPSIT{nnr:*}VRRAF | LFcinB-CLICK | Free | Free | Linear | L | * = triazole linkage | 23 | Anticancer | <2 % Hemolysis at 10 µM | Human | Lf-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | RRWQWR{nt:Acet}{ct:Amid} | LFcinB1 | Amidation | Acetylation | Linear | L | None | 6 | Anticancer | <2 % Hemolysis at 10 µM | Human | Lf-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCA | hLF11 | Free | Free | Linear | L | None | 11 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWSA | hLF11C10S | Free | Free | Linear | L | None | 11 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCA{cyc:N-C} | Cyclo-hLF11 | Free | Free | Cyclic | L | None | 11 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCA{cyc:N-C} | Cyclo-hLF11C10S | Free | Free | Cyclic | L | None | 11 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCAGRRRRSVQWCA | Dimer hLF11 | Free | Free | Linear | L | None | 22 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWCT | bLF10 | Free | Free | Linear | L | None | 10 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWST | bLF10C9S | Free | Free | Linear | L | None | 10 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWCT{cyc:N-C} | Cyclo-bLF10 | Free | Free | Cyclic | L | None | 10 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWCTAPRKNVRWCT | Dimer bLF10 | Free | Free | Linear | L | None | 20 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWCTISQPEW | bLF16 | Free | Free | Linear | L | None | 16 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCAPRRWQWR{ct:Amid} | hLF11-P-LFcinB1 | Amidation | Free | Linear | L | None | 18 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCAGGRRWQWR{ct:Amid} | hLF11-GG-LFcinB1 | Amidation | Free | Linear | L | None | 19 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Anticancer | 90 % Hemolysis at 10 µM | Human | Bee Venom | Helical | NA | ||
| 28422156 | 2017 | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEWGCPCQL | Laterosporulin10 (LS10) | Free | Free | Linear | L | None | 53 | Anticancer | 0 % Hemolysis at 1-40 µM | Rabbit | Brevibacillus Sp. Strain Skdu10 | Randomic structures in 5% SDS and 100% TFE | Non-hemolytic | ||
| 27937055 | 2017 | GHHNGR | oleylpeptide | Free | Free | Linear | L | None | 6 | Anticancer | 1.3 ± 0.04 % Hemolysis at 2 mM | Human | Resin | β-Turns and Bent | Non-hemolytic | ||
| 37746048 | 2023 | DASTKKLSECLRRIGDELDS | BHP | Free | Free | Linear | L | None | 20 | Antitumor | 0 % Hemolysis at 3-200 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 37867694 | 2023 | RWQWRWQWR | [Pal] | Free | Free | Linear | L | None | 9 | Anticancer | 13.2 % Hemolysis at 200 μg/mL | Human | Bovine Lactoferricin | α-Helical | NA | ||
| 37867694 | 2023 | {nnr:Ahx}RWQWRWQWR | Ahx-[Pal] | Free | Free | Linear | L | Ahx = amino hexanoic acid | 9 | Anticancer | 7.7 % Hemolysis at 200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 37867694 | 2023 | RWQWRWQW{nnr:O} | 9[Orn] [Pal] | Free | Free | Linear | L | O = L-Ornithine | 8 | Anticancer | 6.6 % Hemolysis at 200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 37734650 | 2024 | KLKSKLMVVCNKIGLLKSLCRKFVKSH | NKL-WT | Free | Free | Linear | L | None | 27 | Antibacterial and Anticancer | 16.3 % Hemolysis at 40 µM | Rabbit | Antarctic Teleost Trematomus Bernacchii | α-Helical | NA | ||
| 37734650 | 2024 | KLKSKLMVVCNKIGLLKSLCRKFVKSH | NKL-WT | Free | Free | Linear | L | None | 27 | Antibacterial and Anticancer | 40.5 % Hemolysis at 80 µM | Rabbit | Antarctic Teleost Trematomus Bernacchii | α-Helical | NA | ||
| 37734650 | 2024 | KLKSKLMVVANKIGLLKSLARKFVKSH | NKL-MUT | Free | Free | Linear | L | None | 27 | Antibacterial and Anticancer | 0.9 % Hemolysis at 5 µM | Rabbit | Antarctic Teleost Trematomus Bernacchii | α-Helical | NA | ||
| 37734650 | 2024 | KLKSKLMVVANKIGLLKSLARKFVKSH | NKL-MUT | Free | Free | Linear | L | None | 27 | Antibacterial and Anticancer | 2.6 % Hemolysis at 80 µM | Rabbit | Antarctic Teleost Trematomus Bernacchii | α-Helical | NA | ||
| 37880286 | 2024 | GIGAVLKVLTTGLPALISWIKRKRQQ | Mel | Free | Free | Linear | L | None | 26 | Anticancer | <40 % Hemolysis at 256 μg/mL | Human | Bee Venom | α-Helical | NA | ||
| 37880286 | 2024 | CGIGAVLKVLTTGLPALISWIKRKRQQ | C-Mel | Free | Free | Linear | L | None | 27 | Anticancer | 30 % Hemolysis at 256 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 37880286 | 2024 | GIGAVLKVLTTGLPALISWIKRKRQQC | Mel-C | Free | Free | Linear | L | None | 27 | Anticancer | <40 % Hemolysis at 256 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 12 | Anticancer, Antimicrobial | 10 % Hemolysis at 14 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 12 | Anticancer, Antimicrobial | 50 % Hemolysis at 62 μM | Human | Synthetic | NA | NA | ||
| 29280948 | 2017 | KWKSFLKTFKSAKKTVLHTALKAISS{nt:Acet}{ct:Amid} | V13K | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial, Anticancer | <20 % Hemolysis at 250 μM | Human | Magainin (African Clawed Frog) | α-Helical | Low hemolytic | ||
| 29643444 | 2018 | TVLRGCWTFSFPPKPCI{ct:Amid} | HECI | Amidation | Free | Linear | L | None | 17 | Anticancer | <15 % Hemolysis at 128 µM | Horse | Frogs (Hylarana Erythraea Chymotrypsin Inhibitor) | NA | NA | ||
| 29670004 | 2018 | FFSLIPKLVKGLISAFK{ct:Amid} | StigA6 | Amidation | Free | Linear | L | None | 17 | Antiparasitic, Antimicrobial, Anticancer | 30 % Hemolysis at 75 µM | Human | Analogs To Stigmurin | Random coil | NA | ||
| 29670004 | 2018 | FFKLIPKLVKGLISAFK{ct:Amid} | StigA16 | Amidation | Free | Linear | L | None | 17 | Antiparasitic, Antimicrobial, Anticancer | 30 % Hemolysis at 75 µM | Human | Analogs To Stigmurin | Random coil | NA | ||
| 29549839 | 2018 | {conj:CH3(CH2)14CO}SKVWRHWRRFWHRAHRKL | PA-C1b | Free | CH3(CH2)14CO | Linear | L | palmitic acid (PA) conjugation of aliphatic acid was designed lipo-chensinin-1b | 14 | Anticancer and Anti-inflammation | 0 % Hemolysis at >500 µM | Human | Designed Lipo-Chensinin-1B | Random coil at aq, β-Strand at TFE solution | Non-hemolytic | ||
| 29904274 | 2018 | RKKRRQRRRLNLKALLAVAKKIL{ct:Amid} | tMP-C | Amidation | Free | Linear | L | None | 23 | Anticancer | 50 % Hemolysis at 77.94 µM | Horse | Modifcation In Mp-N-Terminal Extension Via Tat-Linked | Random-coil at aq, α-Helical at membrane mimic solution | NA | ||
| 29770868 | 2018 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | melittin monomer | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anticancer | 100 % Hemolysis at 10 μM | mouse | Bee Venom | α-Helix | NA | ||
| 29842923 | 2018 | SILPTIVSFLSKVF | Temporin-1Ga | Free | Free | Linear | L | None | 14 | Antibacterial, Antifungal, Anticancer | 50 % Hemolysis at 12.5 μM | Human | Frog Rana Grylio | NA | NA | ||
| 29842923 | 2018 | FLPFLKSILGKIL | Temporin-1OLa | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal, Anticancer | 50 % Hemolysis at 50 μM | Human | Frog Rana Okaloosae | α-Helical | NA | ||
| 29931753 | 2018 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:-NH2/Ce6} | MEL/Ce6 | Free | -NH2/Ce6 | Linear | L | Ce6 = porphyrin derivatives chlorin e6 | 26 | Anticancer | >30 % Hemolysis at 40 μM | mouse | Modified Melittin | NA | NA | ||
| 29931753 | 2018 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:NH2/Ce6@HA} | MEL/Ce6@HA | Free | NH2/Ce6@HA | Linear | L | Ce6 = porphyrin derivatives chlorin e6, HA = hyaluronic acid | 26 | Anticancer | >10 % Hemolysis at 40 μM | mouse | Modified Melittin | NA | NA | ||
| 30087268 | 2018 | ALWKDILKNLLKAALNEINQIVQ{ct:Amid} | L10, 11-DPS3 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Anticancer | 50 % Hemolysis at 3.44 μM | Horse | Analogs Of Dermaseptin-Ps3 | aqueous = Random coils, membrane-mimicking solution = α-Helical | NA | ||
| 29760411 | 2018 | L/I-A-L/I-L/I-L/I-R-L/I -L/I-V-K-L/I-(K-K-S-L/I-T-L/I-K-V-L/I-L/I-R-I/L){cyc:N-C} | Paenialvin-A | Free | Free | Bicyclic | Mix | None | 23 | Antibacterial,Antitumor | 3.61 % Hemolysis at 50 μg/ml | Rabbit | Bacteria Paenibacillus Alvei Dsm 29 | NA | Non-hemolytic | ||
| 30240951 | 2018 | VNWKKILGKIIKVVK{ct:Amid} | Lasioglossin-III | Amidation | Free | Linear | L | None | 15 | Antimicrobial, Anticancer | >35 % Hemolysis at 10 µM | Human | Derived From Bee Venom | α-Helix | NA | ||
| 30240951 | 2018 | VNWKKILGKIIKVVK{ct:Amid} | Lasioglossin-III | Amidation | Free | Linear | L | None | 15 | Antimicrobial, Anticancer | 100 % Hemolysis at 100 µM | Human | Derived From Bee Venom | α-Helix | NA | ||
| 30387611 | 2018 | GLPICGETCVFGKCNTPGCSCRRPICYKN{cyc:N-C} | Rivi1 | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≫10 µM | Human | Plant Rinorea Virgata | Loop | NA | ||
| 30387611 | 2018 | GSYLCGETCVQGKCYTPGCTCSWPICKKN{cyc:N-C} | Rivi2 | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≫10 µM | Human | Plant Rinorea Virgata | Loop | NA | ||
| 30387611 | 2018 | GLPICGETCLLGKCYTPGCSCRRPVCYKN{cyc:N-C} | Rivi3 | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≫10 µM | Human | Plant Rinorea Virgata | Loop | NA | ||
| 30622471 | 2018 | GRFKRFRKKLKRLWHKVGPFVGPILHY | ChMAP-28 | Free | Free | Linear | L | None | 27 | Anticancer | <10 % Hemolysis at 10 µM | Human | Capra Hircus Goat Leukocytes | α-Helix | NA | ||
| 30622471 | 2018 | GRFKRFRKKLKRLWHKVGPFVGPILHY | ChMAP-28 | Free | Free | Linear | L | None | 27 | Anticancer | 50 % Hemolysis at ~100 µM | Human | Capra Hircus Goat Leukocytes | α-Helix | NA | ||
| 30701481 | 2019 | GLPLLISWIKRKRQQGSKKPVPIIYCNRRTGKCQRM | Hybrid Peptide | Free | Free | Linear | L | None | 36 | Antibacterial, Anticancer | 0 % Hemolysis at 45 μmol/L | Sheep | Mutant Fragments Of Melittin And Thanatin | x | Non-hemolytic | ||
| 30612735 | 2019 | FLSLIPHIASGIASLVKNF{ct:Amid} | Phylloseptin-PBa1 | Amidation | Free | Linear | L | None | 19 | Antimicrobial, Anticancer | 50 % Hemolysis at 18.6 µM | Horse | Leaf Forg (Phyllomedusa Burmeisteri) | α-Helix | NA | ||
| 30612735 | 2019 | FLSLLPHIASGIASLVSKF{ct:Amid} | Phylloseptin-PBa2 | Amidation | Free | Linear | L | None | 19 | Antimicrobial, Anticancer | 50 % Hemolysis at 15.82 µM | Horse | Leaf Forg (Phyllomedusa Burmeisteri) | α-Helix | NA | ||
| 30612735 | 2019 | FLSLIPHIVSGVAALANHL{ct:Amid} | Phylloseptin-PBa3 | Amidation | Free | Linear | L | None | 19 | Antimicrobial, Anticancer | 50 % Hemolysis at 52.98 µM | Horse | Leaf Forg (Phyllomedusa Burmeisteri) | α-Helix | NA | ||
| 30449002 | 2019 | IWLTALKFLGKNLGKLAKQQLAKL{ct:Amid} | LyeTxI-b | Amidation | Free | Linear | L | None | 24 | Anticancer, Antitumor | ~35 % Hemolysis at 100 µM | Human | Spider Venom Lycosa Erythrognatha | α-Helix | Low hemolytic | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | 0 % Hemolysis at 18.75 µM | Fish | Catfish Clarias Gariepinus | α-Helix | Non-hemolytic | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | <20 % Hemolysis at 150 µM | Fish | Catfish Clarias Gariepinus | α-Helix | NA | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | 39 % Hemolysis at 300 µM | Fish | Catfish Clarias Gariepinus | α-Helix | NA | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | 0 % Hemolysis at 75 µM | Human | Catfish Clarias Gariepinus | α-Helix | Non-hemolytic | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | <3 % Hemolysis at 150 µM | Human | Catfish Clarias Gariepinus | α-Helix | NA | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | 6 % Hemolysis at 300 µM | Human | Catfish Clarias Gariepinus | α-Helix | NA | ||
| 30794440 | 2019 | RQCKAESNTFTGICIAKPPCRQACIREKFTDGHCSKVLRRCLCTKRC | NoD173 | Free | Free | Linear | L | None | 47 | Antitumor, Antiproliferative, Antimicrobial | ~12 % Hemolysis at 100 µM | Human | Plant Nicotiana Occidentalis Defensin 173 (Nod173) | single α-Helix braced by 3 disulfide bonds to a Triple-Stranded antiparallel b-Sheet | Low hemolytic | ||
| 31199859 | 2019 | FIGAIARLLSKIF | BmKn-2 | Free | Free | Linear | L | None | 13 | Antimicrobial, Anticancer, Antibiofilm | 100 % Hemolysis at 800 μM | Sheep | Scorpion Mesobuthus Martensii Karsch | α-Helix | NA | ||
| 31375699 | 2019 | KIFKKFKTIIKKVWRIFGRF | AmphiArc2 | Free | Free | Linear | L | None | 20 | Anticancer | 50 % Hemolysis at >15 μM | Human | Synthetic Peptide | water = unstructured, hydrophobic environment (in 50% v/v water:2,2-trifuoroethanol, TFE) = α-Helix | NA | ||
| 31426323 | 2019 | ALWKTLLKHVGKAAGKAALNAVTDMVNQ{ct:Amid} | Der-PS4 | Amidation | Free | Linear | L | None | 28 | Antimicrobial, Antibiofilm, Antiproliferative, Anticancer | 50 % Hemolysis at 128 μM | Horse | Waxy Monkey Tree Frog, Phyllomedusa Sauvagii | mimetic environment(DOPE, DOPC and DOPG, TFE) = α-Helix | NA | ||
| 31062442 | 2019 | LKKLLKLLKKLLKL{ct:Amid} | LK | Amidation | Free | Linear | L | None | 14 | Antitumor | 60 % Hemolysis at 200 μM | Mouse | Synthetic Cell‐Penetrating Peptides (Cpps) | TFE/water(pH = 7.4, pH = 6) = α-Helix | NA | ||
| 31062442 | 2019 | LHHLLHHLHHLLHH{ct:Amid} | LH | Amidation | Free | Linear | L | None | 14 | Antitumor | 0 % Hemolysis at 200 μM | Mouse | Synthetic Cell‐Penetrating Peptides (Cpps) | TFE/water(pH = 7.4, pH = 6) = α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 18 % Hemolysis at 400 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Low hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 5 % Hemolysis at 200 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Low hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 100 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 50 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 25 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 12.5 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 6.25 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 3.125 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31635388 | 2019 | GLWSKIKDAA-KTAGKAALGFVNEMV | DPT9 | Free | Free | Linear | L | None | 25 | Antimicrobial, Antibiofilm, Anticancer | 50 % Hemolysis at 210 μM | Horse | Derived From Frog Phyllomedusa Tarsius Dpt9 | NA | NA | ||
| 31635388 | 2019 | GLWSKIKKAA-KTAGKAALGFVNKMV | K8, 23-DPT9 | Free | Free | Linear | L | None | 25 | Antimicrobial, Antibiofilm, Anticancer | 50 % Hemolysis at 107 μM | Horse | Analogue And Modified Dtp9 | NA | Low hemolytic | ||
| 31927997 | 2020 | KLLKLLKKLLKLLK | KL1 | Free | Free | Linear | L | None | 14 | Anticancer | 10 % Hemolysis at 0.52 μM | Human | Synthetic Peptide | PBS buffer = α-Helical, deionized water and 0.9% NaCl = Random coil | NA | ||
| 31927997 | 2020 | KELKLLKKLLKLLK | L2E | Free | Free | Linear | L | None | 14 | Anticancer | 10 % Hemolysis at 61.7 μM | Human | Kl1 Analogues. | Random coil, 10%TFE = single Helix | NA | ||
| 31927997 | 2020 | KQLKLLKKLLKLLK | L2Q | Free | Free | Linear | L | None | 14 | Anticancer | 10 % Hemolysis at 35.5 μM | Human | Kl1 Analogues. | NA | NA | ||
| 31927997 | 2020 | KKLKLLKKLLKLLK | L2K | Free | Free | Linear | L | None | 14 | Anticancer | 10 % Hemolysis at 19.5 μM | Human | Kl1 Analogues. | NA | NA | ||
| 32443921 | 2020 | FLGAILKIGHALAKTVLPMVTNAFKPKQ | Figainin 2 | Free | Free | Linear | L | None | 28 | Antibacterial, Anticancer, Anti-Epimastigote, Antiviral, Antitrypanosomal, exhibits immunomodulatory effects in human neutrophils | 50 % Hemolysis at 48.9 μM | Human | Skin Chaco Tree Frog, Boana Raniceps | α-Helix, Milli-Q water and 10% (v/v) TFE = Random coil, 30% and 50% (v/v) TFE = α-Helix | NA | ||
| 32443921 | 2020 | FLGAILKIGHALAKTVLPMVTNAFKPKQ | Figainin 2 | Free | Free | Linear | L | None | 28 | Antibacterial, Anticancer, Anti-Epimastigote, Antiviral, Antitrypanosomal, exhibits immunomodulatory effects in human neutrophils | 23 % Hemolysis at 32 μM | Human | Skin Chaco Tree Frog, Boana Raniceps | α-Helix, Milli-Q water and 10% (v/v) TFE = Random coil, 30% and 50% (v/v) TFE = α-Helix | NA | ||
| 32443921 | 2020 | FLGAILKIGHALAKTVLPMVTNAFKPKQ | Figainin 2 | Free | Free | Linear | L | None | 28 | Antibacterial, Anticancer, Anti-Epimastigote, Antiviral, Antitrypanosomal, exhibits immunomodulatory effects in human neutrophils | 9 % Hemolysis at 16 μM | Human | Skin Chaco Tree Frog, Boana Raniceps | α-Helix, Milli-Q water and 10% (v/v) TFE = Random coil, 30% and 50% (v/v) TFE = α-Helix | NA | ||
| 32347293 | 2020 | FLGALFKVASKLVPAAICSISKKC | Brevinin-1GHd | Free | Free | Linear | L | None | 24 | Antimicrobial, Anticancer, Antibiotic, Antibiofilm | 13 % Hemolysis at 32 μM | Horse | Frog Skin, Hylarana Guenther | aqueous(10 mM NH4AC buffer) = Random coil, membrane-mimetic environment (50% TFE in 10 mM NH4AC)membrane-mimetic environment (50% TFE in 10 mM NH4AC) = α-Helix | NA | ||
| 32582642 | 2020 | ALWKDMLKGIGKLAGKAALGAVKTLV{ct:Amid} | Dermaseptin-PP | Amidation | Free | Linear | L | None | 26 | Antimicrobial, Antitumor | <20 % Hemolysis at 16 μM | Horse | Frog Phyllomedusa Palliata | 50% TFE-10 mmol/L NH4Ac solution (MME) = α-Helical | NA | ||
| 32582642 | 2020 | ALWKDMLKGIGKLAGKAALGAVKTLV{ct:Amid} | Dermaseptin-PP | Amidation | Free | Linear | L | None | 26 | Antimicrobial, Antitumor | 50 % Hemolysis at 38.77 μM | Horse | Frog Phyllomedusa Palliata | 50% TFE-10 mmol/L NH4Ac solution (MME) = α-Helical | NA | ||
| 32437150 | 2020 | GIP-CGESCVYIPCITAALGCSCKSKVCYRN{cyc:N-C} | viar 1 | Free | Free | Cyclic | L | None | 30 | Anticancer | 50 % Hemolysis at 11.1 ± 0.02 μM | Human | Plant Viola Arcuata | α-Helical | Low hemolytic | ||
| 32437150 | 2020 | GIP-CGESCVWIPCISAAIGCSCKSKVCYRN{cyc:N-C} | cO13 | Free | Free | Cyclic | L | None | 30 | Anticancer | 50 % Hemolysis at 14.9 ± 0.01 μM | Human | Plant Viola Arcuata | α-Helical | Low hemolytic | ||
| 32437150 | 2020 | GLPVCGETCVGGTCNTPG--CSCSWPVCTRN{cyc:N-C} | kalata S | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≥50 μM | Human | Plant Viola Arcuata | NA | NA | ||
| 32567085 | 2020 | FKRIVQRIKDFLR{nt:NA}{ct:Amid} | 1 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | LKRIVQRIKDFLR{nt:NA}{ct:Amid} | 2 | Amidation | NA | Linear | L | None | 13 | Antibacterial, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | AKRIVQRIKDFLR{nt:NA}{ct:Amid} | 3 | Amidation | NA | Linear | L | None | 13 | Antibacterial, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | F{nnr:κ}RIVQRILDFLR{nt:Acet}{ct:Amid} | 4 | Amidation | Acetylation | Linear | L | κ = κ | 13 | Antibacterial, Anticancer | 50 % Hemolysis at 450 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FK({nnr:SA})RIVQRILDFLR{nt:Acet}{ct:Amid} | 5 | Amidation | Acetylation | Linear | L | SA = SA | 14 | Antibacterial, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQRIRDFLR{nt:NA}{ct:Amid} | 6 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQRIRDFLR{nt:Acet}{ct:Amid} | 7 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQ{nnr:κ}IKDFLR{nt:NA}{ct:Amid} | 8 | Amidation | NA | Linear | L | κ = κ | 13 | Antibacterial, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQLIKDFLR{nt:NA}{ct:Amid} | 9 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 114 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQLIKDFLR{nt:Acet}{ct:Amid} | 10 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 227 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQRIKDLLR{nt:NA}{ct:Amid} | 11 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQRIKDLLR{nt:Acet}{ct:Amid} | 12 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQIIKKFLR{nt:NA}{ct:Amid} | 13 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 361 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQIIKKFLR{nt:Acet}{ct:Amid} | 14 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 292 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQLLKKLLR{nt:NA}{ct:Amid} | 15 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 411 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQLLKKLLR{nt:Acet}{ct:Amid} | 16 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 185 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRILQRIKDFLR{nt:NA}{ct:Amid} | 17 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRILQRIKDFLR{nt:Acet}{ct:Amid} | 18 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32126228 | 2020 | VRRFPWWWPFLRR | Tritrpticin | Free | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Trp-Rich Porcine Cathelicidin Peptide | NA | NA | ||
| 32126228 | 2020 | VRRFPWWWPFLRR{ct:Amid} | Tritrp-Arg | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at 62.2 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | V({nnr:Agb})({nnr:Agb})FPWWWPFL({nnr:Agb})({nnr:Agb}){ct:Amid} | Tritrp-Agb | Amidation | Free | Linear | L | Agb = (S)-2-amino-4 guanidinobutyric acid | 13 | Anticancer | 50 % Hemolysis at 34.6 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | V({nnr:hArg})({nnr:hArg})FPWWWPFL({nnr:hArg})({nnr:hArg}){ct:Amid} | Tritrp-hArg | Amidation | Free | Linear | L | hArg = homo-arginine Arg Derivative | 13 | Anticancer | 50 % Hemolysis at 41.3 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VKKFPWWWPFLKK{ct:Amid} | Tritrp-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | V({nnr:Dap})({nnr:Dap})FPWWWPFL({nnr:Dap})({nnr:Dap}){ct:Amid} | Tritrp-Dap | Amidation | Free | Linear | L | Dap = 2,3-diaminopropionic acid Lys Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | V({nnr:Dab})({nnr:Dab})FPWWWPFL({nnr:Dab})({nnr:Dab}){ct:Amid} | Tritrp-Dab | Amidation | Free | Linear | L | Dab = 2,4-diaminobutyric acid Lys Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | V{nnr:O}{nnr:O}FPWWWPFL{nnr:O}{nnr:O}{ct:Amid} | Tritrp-Orn | Amidation | Free | Linear | L | O = L-Ornithine | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFAWWWAFLRR{ct:Amid} | Tritrp-P59A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at 52.5 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VKKFAWWWAFLKK{ct:Amid} | Tritrp-P59A-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFAWWWPFLRR{ct:Amid} | Tritrp-P5A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VKKFAWWWPFLKK{ct:Amid} | Tritrp-P5A-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWWWAFLRR{ct:Amid} | Tritrp-P9A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at 29.3 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VKKFPWWWAFLKK{ct:Amid} | Tritrp-P9A-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPFFFPFLRR{ct:Amid} | Tritrp-W678F | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFP({nnr:bTA})({nnr:bTA})({nnr:bTA})PFLRR{ct:Amid} | Tritrp-W678bTA | Amidation | Free | Linear | L | bTA = β-3-benzothienyl-1-AlaTrpDerivative | 13 | Anticancer | 50 % Hemolysis at 12.2 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFP({nnr:hW})WWPFLRR{ct:Amid} | Tritrp-W6hW | Amidation | Free | Linear | L | hW = 5-hydroxytryptophan Trp Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPW({nnr:hW})WPFLRR{ct:Amid} | Tritrp-W7hW | Amidation | Free | Linear | L | hW = 5-hydroxytryptophan Trp Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWW({nnr:hW})PFLRR{ct:Amid} | Tritrp-W8hW | Amidation | Free | Linear | L | hW = 5-hydroxytryptophan Trp Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFP({nnr:hW})({nnr:hW})({nnr:hW})PFLRR{ct:Amid} | Tritrp-W678hW | Amidation | Free | Linear | L | hW = 5-hydroxytryptophan Trp Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPAWWPFLRR{ct:Amid} | Tritrp-W6A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWAWPFLRR{ct:Amid} | Tritrp-W7A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWWAPFLRR{ct:Amid} | Tritrp-W8A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPAAWPFLRR{ct:Amid} | Tritrp-W67A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPAWAPFLRR{ct:Amid} | Tritrp-W68A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWAAPFLRR{ct:Amid} | Tritrp-W78A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPAAAPFLRR{ct:Amid} | Tritrp-W678A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPYWWPFLRR{ct:Amid} | Tritrp-W6Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWYWPFLRR{ct:Amid} | Tritrp-W7Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWWYPFLRR{ct:Amid} | Tritrp-W8Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPYYWPFLRR{ct:Amid} | Tritrp-W67Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPYWYPFLRR{ct:Amid} | Tritrp-W68Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWYYPFLRR{ct:Amid} | Tritrp-W78Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPYYYPFLRR{ct:Amid} | Tritrp-W678Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | CVRRFPWWYPFLRRC{cyc:N-C}{ct:Amid} | Tritrp-DiSu* | Amidation | Free | Cyclic | L | None | 15 | Anticancer | 50 % Hemolysis at 20.9 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | GIGKWLHSAKKFGKAFVGEIMNS | MagaininF5W-Lys | Free | Free | Linear | L | None | 23 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | GIGRWLHSARRFGRAFVGEIMNS | MagaininF5W-Arg | Free | Free | Linear | L | None | 23 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FPVTWRWWRWWRG{ct:Amid} | PuroA-Arg | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FPVTWKWWKWWKG{ct:Amid} | PuroA-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin-Arg | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | ILPWKWPWWPWKK{ct:Amid} | Indolicidin-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FRVTWRTKWWKG{ct:Amid} | PuroB3 | Amidation | Free | Linear | L | None | 12 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FRVT({nnr:hW})RTK({nnr:hW})({nnr:hW})KG{ct:Amid} | PuroB3-hW | Amidation | Free | Linear | L | hW = 5-hydroxytryptophan Trp Derivative | 12 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | GALFLGFLGAAGSTMGAWSQPKKKRKV{nt:Acet}{ct:CM = CysteAmidation} | MPG | CM = CysteAmidation | Acetylation | Linear | L | CM = CysteAmidation | 27 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | KETWWETWWTEWSQPKKKRKV{nt:Acet}{ct:CM = CysteAmidation} | Pep-1 | CM = CysteAmidation | Acetylation | Linear | L | CM = CysteAmidation | 21 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | RRWWRF{nt:Acet}{ct:Amid} | Combi-1 | Amidation | Acetylation | Linear | L | None | 6 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FRWWHR{nt:Acet}{ct:Amid} | Combi-2 | Amidation | Acetylation | Linear | L | None | 6 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | RAWVAWR{ct:Amid} | LysH | Amidation | Free | Linear | L | None | 7 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | TRSSRAGLQFPVGRVHRLLRK | Buforin-2 | Free | Free | Linear | L | None | 21 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | GIGAVLKVLTTGLPAALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 21 | Anticancer | 50 % Hemolysis at ≤6.5 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32752241 | 2020 | HHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2 [T2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 10 % Hemolysis at 1.4 μM | Human | Phylum Placozo Trichoplax Adhaerens | Helical | NA | ||
| 32752241 | 2020 | RHHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2A [T2R1] | Amidation | Free | Linear | L | None | 21 | Antimicrobial, Anticancer | 10 % Hemolysis at 3 μM | Human | Analog Of Trichoplaxin-2 | Helical | NA | ||
| 32752241 | 2020 | GIKKAVGKALKGLKGLLKALGES{ct:Amid} | Adepantin-1A [A1A] | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Anticancer | 10 % Hemolysis at 25 μM | Human | Adepantin-1 Analog | Helical | NA | ||
| 32752241 | 2020 | GIGKFLKKAKKFGKAFVLILKK{ct:Amid} | Pexiganan-L18 [PEXA] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 10 % Hemolysis at 1.6 μM | Human | Pexiganan Analog | Helical | NA | ||
| 32752241 | 2020 | GIKKWVKGVAKGVAKDLAKKIL{ct:Amid} | Flexampin [FLEX] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 10 % Hemolysis at 6 μM | Human | Template From Ranatuerin-2Csa | Helical | NA | ||
| 32752241 | 2020 | GIGREIIKKIIKKIGKKIGRII{ct:Amid} | Zyk-1 [ZYK1] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 10 % Hemolysis at 3 μM | Human | Zyk Strain Of Bacillus Oryziterrae Peptide | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKVALKAL{ct:Amid} | DiPGLa-H [PG2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 10 % Hemolysis at 3 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKGALKAL{ct:Amid} | Kiadin-1 [KIA1] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 10 % Hemolysis at 3 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIGKKILKALKGALKELA{ct:Amid} | Mapegin [MAPA] | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Anticancer | 10 % Hemolysis at 1.7 μM | Human | Syntheitc Cell-Penetrating Peptide | Helical | NA | ||
| 32752241 | 2020 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MP1 [MP1] | Amidation | Free | Linear | L | None | 14 | Antimicrobial, Anticancer | 10 % Hemolysis at 20 μM | Human | Synthetic Amps | Helical | NA | ||
| 32752241 | 2020 | HHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2 [T2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 20 % Hemolysis at 3 μM | Human | Phylum Placozo Trichoplax Adhaerens | Helical | NA | ||
| 32752241 | 2020 | RHHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2A [T2R1] | Amidation | Free | Linear | L | None | 21 | Antimicrobial, Anticancer | 20 % Hemolysis at 25 μM | Human | Analog Of Trichoplaxin-2 | Helical | NA | ||
| 32752241 | 2020 | GIKKAVGKALKGLKGLLKALGES{ct:Amid} | Adepantin-1A [A1A] | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Anticancer | 20 % Hemolysis at 80 μM | Human | Adepantin-1 Analog | Helical | NA | ||
| 32752241 | 2020 | GIGKFLKKAKKFGKAFVLILKK{ct:Amid} | Pexiganan-L18 [PEXA] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 20 % Hemolysis at 7 μM | Human | Pexiganan Analog | Helical | NA | ||
| 32752241 | 2020 | GIKKWVKGVAKGVAKDLAKKIL{ct:Amid} | Flexampin [FLEX] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 20 % Hemolysis at 25 μM | Human | Template From Ranatuerin-2Csa | Helical | NA | ||
| 32752241 | 2020 | GIGREIIKKIIKKIGKKIGRII{ct:Amid} | Zyk-1 [ZYK1] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 20 % Hemolysis at 8 μM | Human | Zyk Strain Of Bacillus Oryziterrae Peptide | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKVALKAL{ct:Amid} | DiPGLa-H [PG2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 20 % Hemolysis at 14 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKGALKAL{ct:Amid} | Kiadin-1 [KIA1] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 20 % Hemolysis at 6 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIGKKILKALKGALKELA{ct:Amid} | Mapegin [MAPA] | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Anticancer | 20 % Hemolysis at 3 μM | Human | Syntheitc Cell-Penetrating Peptide | Helical | NA | ||
| 32752241 | 2020 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MP1 [MP1] | Amidation | Free | Linear | L | None | 14 | Antimicrobial, Anticancer | 20 % Hemolysis at 37 μM | Human | Synthetic Amps | Helical | NA | ||
| 32752241 | 2020 | HHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2 [T2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 50 % Hemolysis at 28 μM | Human | Phylum Placozo Trichoplax Adhaerens | Helical | NA | ||
| 32752241 | 2020 | RHHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2A [T2R1] | Amidation | Free | Linear | L | None | 21 | Antimicrobial, Anticancer | 50 % Hemolysis at 7000 μM | Human | Analog Of Trichoplaxin-2 | Helical | Low hemolytic | ||
| 32752241 | 2020 | GIKKAVGKALKGLKGLLKALGES{ct:Amid} | Adepantin-1A [A1A] | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Anticancer | 50 % Hemolysis at 125 μM | Human | Adepantin-1 Analog | Helical | NA | ||
| 32752241 | 2020 | GIGKFLKKAKKFGKAFVLILKK{ct:Amid} | Pexiganan-L18 [PEXA] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 50 % Hemolysis at 520 μM | Human | Pexiganan Analog | Helical | NA | ||
| 32752241 | 2020 | GIKKWVKGVAKGVAKDLAKKIL{ct:Amid} | Flexampin [FLEX] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 50 % Hemolysis at 1600 μM | Human | Template From Ranatuerin-2Csa | Helical | Low hemolytic | ||
| 32752241 | 2020 | GIGREIIKKIIKKIGKKIGRII{ct:Amid} | Zyk-1 [ZYK1] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 50 % Hemolysis at 29 μM | Human | Zyk Strain Of Bacillus Oryziterrae Peptide | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKVALKAL{ct:Amid} | DiPGLa-H [PG2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 50 % Hemolysis at 18 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKGALKAL{ct:Amid} | Kiadin-1 [KIA1] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 50 % Hemolysis at 20 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIGKKILKALKGALKELA{ct:Amid} | Mapegin [MAPA] | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Anticancer | 50 % Hemolysis at 20 μM | Human | Syntheitc Cell-Penetrating Peptide | Helical | NA | ||
| 32752241 | 2020 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MP1 [MP1] | Amidation | Free | Linear | L | None | 14 | Antimicrobial, Anticancer | 50 % Hemolysis at 170 μM | Human | Synthetic Amps | Helical | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala} | 1 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K | 2 | Free | Free | Linear | L | (N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine | 7 | Antibacterial, Anticancer | 78.1 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K | 4 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 5 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial, Anticancer | 36 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 11 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | 33.3 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 15 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial, Anticancer | 94.2 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala} | 1 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial, Anticancer | 19.7 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K | 2 | Free | Free | Linear | L | (N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine | 7 | Antibacterial, Anticancer | 100.1 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K | 4 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 5 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial, Anticancer | 22.5 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 11 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | 40.7 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 15 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial, Anticancer | 87.1 % Hemolysis at 150 µM | Canine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala} | 1 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K | 2 | Free | Free | Linear | L | (N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine | 7 | Antibacterial, Anticancer | 100 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K | 4 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 5 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial, Anticancer | 10.2 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 11 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | 11.3 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 15 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial, Anticancer | 99.5 % Hemolysis at 150 µM | Rat | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala} | 1 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial, Anticancer | 32.5 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K | 2 | Free | Free | Linear | L | (N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K | 4 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 5 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 11 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | 17.4 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 15 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Bovine | Synthetic Amps | NA | Low hemolytic | ||
| 32872343 | 2020 | SALRGCWTFSIPPKPCL{ct:Amid} | F-SL | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Anticancer | ≥10 % Hemolysis at 512 μM | Horse | Sl-Bbi Analogues | NH4AC = β-Sheet and Random coil, 50%TFE/NH4AC = β-Sheet and Random coil | Low hemolytic | ||
| 32967114 | 2020 | FIGTLIPLALGALTKLFK{ct:Amid} | Figainin 1 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Anticancer, Anti-infective, Antitrypanosomal | 50 % Hemolysis at 10 μM | Human | Frog Boana Raniceps | water and 10% (v/v) TFE = Disordered, 30% (v/v) and 50% (v/v) TFE = α-Helical | NA | ||
| 33063186 | 2020 | FKLVWKLLKKLALKL | Aper1 | Free | Free | Linear | L | None | 15 | Anticancer, Antimicrobial | 10 % Hemolysis at 5.96 μM | Human | Derived From The Thermophilic Bacteria Aeropyrum Pernix. | NA | NA | ||
| 33194795 | 2020 | RFRLPFRRPPIRIHPPPFYPPFRRFL{ct:Amid} | ChBac3.4-NH2(caprine proline-rich bactenecin) | Amidation | Free | Linear | L | None | 26 | Antitumor, Antimicrobial, Antibiofilm | 25 ± 2 % Hemolysis at 64 μM | Human | Domestic Goat Capra Hircus | NA | NA | ||
| 33194795 | 2020 | RFRLPFRRIHPPPFVRIHPPPFYRRFL | ChBac3.4-1-COOH | Free | Free | Linear | L | None | 27 | Antitumor, Antibacterial | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Full-Lenght Variants | NA | Low hemolytic | ||
| 33442249 | 2021 | RADARADARADARADA{nt:Acet}{ct:Amid} | RADA16-I | Amidation | Acetylation | Linear | L | None | 16 | Antitumor, self-assembling peptide | <5 % Hemolysis at 9 mg/mL | Rabbit | Synthetic Pepetide | NA | NA | ||
| 33669976 | 2021 | {nnr:Methyldecanoyl}-{nnr:MePro}-{nnr:AHMOD}-A-{nnr:Aib}-I-{nnr:Iva}-{nnr:βAla}-Alaol-{nnr:Glyol}{nt:amino group}{ct:hydroxyl} | EmiA | hydroxyl | amino group | Linear | L | MePro = Methylproline, AHMOD = 2-Amino-3-hydroxy-4-methyl-2-pentenoic acid, Aib = α-Amino isobutyric acid, Iva = Isovaline, βAla = β-Alanine{nnr:Bala} – β-Alanine , Glyol = Glycine with a hydroxyl modification, Methyldecanoyl = Methyldecanoyl | 9 | Antifungal, Anticancer | 12.6 % Hemolysis at 20 µM | Human | Derived From The Alkalophilic Fungus Emericellopsis Alkalina | NA | NA | ||
| 33582221 | 2021 | ALWKDLLKNVGIAAGKAALNKVTDMVNQ{ct:Amid} | DRS-TO | Amidation | Free | Linear | L | None | 28 | Anticancer, Antimicrobial | 50 % Hemolysis at 436.7 µM | Horse | Leaf Frog Phyllomedusa Tomopterna | Helical | Low hemolytic | ||
| 33244888 | 2021 | IFWLFRGKADVAL{ct:Amid} | neuroVAL | Amidation | Free | Linear | L | None | 13 | Anticancer, Antimicrobial | 50 % Hemolysis at >64 µM | Human | Agelaia-Mpi Analogues | 30% TFE = α-Helical | Low hemolytic | ||
| 33244888 | 2021 | ILGTILGLLKGL{ct:Amid} | protonectin | Amidation | Free | Linear | L | None | 12 | Anticancer, Antimicrobial | 50 % Hemolysis at >64 µM | Human | Wasp Parachartergus Fraternus | 30% TFE = α-Helical | Low hemolytic | ||
| 33244888 | 2021 | IFGTILGFLKGL{ct:Amid} | protonectin-F | Amidation | Free | Linear | L | None | 12 | Anticancer, Antimicrobial | 50 % Hemolysis at >64 µM | Human | Protonectin Analogues | 30% TFE = α-Helical | Low hemolytic | ||
| 33676184 | 2021 | KWKLFKKIKFLHSAKKF | CE-MA | Free | Free | Linear | L | None | 17 | Antibacterial, Antiviral, Antiparasitic, Antifungal, Anticancer | >20 % Hemolysis at 500 μg/ml | Human | Synthetic Peptide Consisting Of Cecropin A And Magenin B | α-Helix | NA | ||
| 34461456 | 2021 | G{d}I{d}G{d}A{d}V{d}L{d}K{d}V{d}L{d}T{d}T{d}G{d}L{d}P{d}A{d}L{d}I{d}S{d}W{d}I{d}K{d}R{d}K{d}R{d}Q{d}Q{d}C{d} | D-melittin | Free | Free | Linear | L | None | 27 | Antitumor | 50 % Hemolysis at 14.8 μM (pH 5.4) | Human | Honeybee Venom | NA | NA | ||
| 34461456 | 2021 | G{d}I{d}G{d}A{d}V{d}L{d}K{d}V{d}L{d}T{d}T{d}G{d}L{d}P{d}A{d}L{d}I{d}S{d}W{d}I{d}K{d}R{d}K{d}R{d}Q{d}Q{d}C{d} | D-melittin | Free | Free | Linear | L | None | 27 | Antitumor | 50 % Hemolysis at 8.5 μM (pH 6.4) | Human | Honeybee Venom | NA | NA | ||
| 34461456 | 2021 | G{d}I{d}G{d}A{d}V{d}L{d}K{d}V{d}L{d}T{d}T{d}G{d}L{d}P{d}A{d}L{d}I{d}S{d}W{d}I{d}K{d}R{d}K{d}R{d}Q{d}Q{d}C{d} | D-melittin | Free | Free | Linear | L | None | 27 | Antitumor | 50 % Hemolysis at 3.3 μM (pH 7.4) | Human | Honeybee Venom | NA | NA | ||
| 34508563 | 2021 | FLGALFKVASKLVPAAICSISKKC | Brevinin-1HL | Free | Free | Linear | L | None | 24 | Antimicrobial, Anticancer, Antibiofilm | 50 % Hemolysis at 11.5 ± 0.2 μM | Horse | Broad-Folded Frog, Hylarana Latouchii | aqueous = Random coil, 50% TFE = α-Helical | NA | ||
| 34508563 | 2021 | FFPLIFGALSSILPKIL | Temporin-HLa | Free | Free | Linear | L | None | 17 | Antimicrobial, Anticancer, Antibiofilm | 50 % Hemolysis at 31.4 ± 0.7 μM | Horse | Broad-Folded Frog, Hylarana Latouchii | aqueous = Random coil, 50% TFE = α-Helical | NA | ||
| 34508563 | 2021 | FLQHIIGALSHIF | Temporin-HLb | Free | Free | Linear | L | None | 13 | Antimicrobial, Anticancer, Antibiofilm | 50 % Hemolysis at 18.6 ± 10.0 mM | Horse | Broad-Folded Frog, Hylarana Latouchii | aqueous = Random coil, 50% TFE = α-Helical | Low hemolytic | ||
| 34867962 | 2021 | FLPLLISALTSLFPKLGK | SSTP1 | Free | Free | Linear | L | None | 18 | Anticancer | 0.25 % Hemolysis at 5 μM | Human | Frog Indosylvirana Aurantiaca Host Defense Peptide | NA | Low hemolytic | ||
| 34941705 | 2021 | ASIGALIQKAIALIKAKAA{nt:Amid}{ct:Amid} | LVTX-9 | Amidation | Amidation | Linear | L | None | 19 | Anticancer | 0 % Hemolysis at 200 μM | Human | Venom Gland Of The Spider Lycosa Vittata | ultrapure water = Random coil, SDS = α-Helical | Non-hemolytic | ||
| 34941705 | 2021 | ASIGALIQKAIALIKAKAA{nt:CH3-(CH2)16CONH}{ct:Amid} | LVTX-9-C18 | Amidation | CH3-(CH2)16CONH | Linear | L | CH3-(CH2)16 = N-Terminal Fatty acid | 23 | Anticancer | 10 % Hemolysis at 25 μM | Human | Lvtx-9, Fatty Acid Modification | ultrapure water = α-Helical, SDS = α-Helical | NA | ||
| 34796903 | 2021 | PARDVLNTTSG{ct:Amid} | P264-G274 | Amidation | Free | Linear | L | None | 11 | Anticancer | 12.2 % Hemolysis at 150 μM | Sheep | Toxin Ps2Aa1 Parasporin-2Aa1 | α-Helix | NA | ||
| 34796903 | 2021 | NNETYFNAVKP{ct:Amid} | Loop1-PS2Aa | Amidation | Free | Linear | L | None | 11 | Anticancer | 18.1 % Hemolysis at 150 μM | Sheep | Toxin Ps2Aa1 Parasporin-2Aa1 | α-Helix | NA | ||
| 34796903 | 2021 | TYFNAVKPPITA{ct:Amid} | Loop2-PS2Aa | Amidation | Free | Linear | L | None | 12 | Anticancer | 9.4 % Hemolysis at 150 μM | Sheep | Toxin Ps2Aa1 Parasporin-2Aa1 | α-Helix | NA | ||
| 34796903 | 2021 | FKPQSGGGKCF{ct:Amid} | Loop1-HCoV-229E | Amidation | Free | Linear | L | None | 11 | Anticancer | 9.2 % Hemolysis at 150 μM | Sheep | Spike Protein Of The Alphacoronavirus Hcov-229E | β-lSheet | NA | ||
| 34796903 | 2021 | FLGWLFKVASK{ct:Amid} | A4W-GGN5 | Amidation | Free | Linear | L | None | 11 | Antimicrobial, Anticancer | 23 % Hemolysis at 150 μM | Sheep | Na | NA | NA | ||
| 35100952 | 2022 | KFVRSRRPRTASCALAFVN | ARF (26-44) | Free | Free | Linear | L | None | 19 | Antibacterial, Anticancer | 5 % Hemolysis at 250 μM | Mouse | Arf(Alternative Reading Frame) Proteins Are P19Arf In Mice | phosphate buffer = Random coil, 50% v/v TFE = α-Helix | Low hemolytic | ||
| 36465844 | 2022 | GVKFAKRFWRFAKKAFKRFEK{nt:Amid} | HAZ | Free | Amidation | Linear | L | None | 21 | Antibacterial, Antibiofilm, Anticancer | 20 % Hemolysis at 120 μM | Human | Synthetic Hybride (Palustrin-1D And Hp(2–20)) Peptide | α-Helical | NA | ||
| 36279986 | 2022 | {nnr:β2,2-Ac6c}-{nnr:Gpn}-{nnr:β2,2-Ac6c}-{nnr:Gpn}-{nnr:β2,2-Ac6c}-{nnr:Gpn}{nt:H}{ct:OMe} | BG6 | OMe | H | Linear | NA | β2,2-Ac6c = 1-aminomethylcyclohexane carboxylic acid, Gpn = 2-(1-(aminomethyl)cyclohexyl)acetic acid | 6 | Anticancer, Anti-migratory and Anti-invasive | 8.05 % Hemolysis at 30 µM/ml | Human | Short Hybrid Synthetic Peptide | NA | Low hemolytic | ||
| 36336133 | 2022 | GLFDIIKKIAESF | Aurein 1.2 | Free | Free | Linear | L | None | 13 | Antimicrobial, Anticancer | >20 % Hemolysis at 500 μg/mL | Human | Skin Of Australian Bell Frogs, Ranoidea Aurea (Formerly Litoria Aurea) And R. Raniformis (Formerly L. Raniformis) | α-Helix | NA | ||
| 36336133 | 2022 | GLFDIIKKIAESF | Aurein 1.2 | Free | Free | Linear | L | None | 13 | Antimicrobial, Anticancer | <35 % Hemolysis at 1000 μg/mL | Human | Skin Of Australian Bell Frogs, Ranoidea Aurea (Formerly Litoria Aurea) And R. Raniformis (Formerly L. Raniformis) | α-Helix | NA | ||
| 36555393 | 2022 | VLTTGLPALISWIKRKRQQGGGGSK{d}L{d}A{d}K{d}L{d}A{d}K{d}K{d}L{d}A{d}K{d}L{d}A{d}K{d}{nt:(FITC)-Ahx = Fluorescein isothiocyanate} | melittin-dKLA 8-26 | Free | (FITC)-Ahx = Fluorescein isothiocyanate | Linear | Mix | None | 38 | Anticancer | <5 % Hemolysis at 40 μM | Mouse | Modified Melittin | NA | Non-hemolytic | ||
| 36668862 | 2023 | LLKKVLALLKKVL{nt:Amid} | Hp-MAP3 | Free | Amidation | Linear | L | None | 13 | Antibacterial, Antibiofilm, Antifungal, Anticancer | ~15 % Hemolysis at 10.8 μM | mouse | Temporin-Pta Analog | 50% TFE or SDS = α-Helix | NA | ||
| 36668862 | 2023 | LLKKVLALLKKVL{nt:Amid} | Hp-MAP3 | Free | Amidation | Linear | L | None | 13 | Antibacterial, Antibiofilm, Antifungal, Anticancer | 25 % Hemolysis at 21.6 μM | mouse | Temporin-Pta Analog | 50% TFE or SDS = α-Helix | NA | ||
| 36668862 | 2023 | LLKKVLALLKKVL{nt:Amid} | Hp-MAP3 | Free | Amidation | Linear | L | None | 13 | Antibacterial, Antibiofilm, Antifungal, Anticancer | ~85 % Hemolysis at 43.3 μM | mouse | Temporin-Pta Analog | 50% TFE or SDS = α-Helix | NA | ||
| 36910465 | 2023 | KLWCKSSQVPQSR | ALA‐A2 | Free | Free | Linear | L | None | 13 | Anticancer | 7.8 ± 10.2 % Hemolysis at 200 µM | Human | Synthetic Peptide Sequence Of Alphalactalbumin | Helix–coil | Low hemolytic | ||
| 36910465 | 2023 | FKCRRWQWRMKKLGAPSITCVR | BMP‐S6 (positive control)[ 5 , 10 ] | Free | Free | Linear | L | None | 22 | Anticancer | 6.0± 9.2 % Hemolysis at 200 µM | Human | Bovine-Derived Acp | coil–Helix | Low hemolytic | ||
| 37310533 | 2023 | RIIDRLWLVRRPQKPKFVLVWVL | PMAP-NC | Free | Free | Linear | L | None | 23 | Antibacterial, Anticancer | 20 % Hemolysis at 64 µM | Human | Pmap-23 Analogs | Helix–hinge–Helix | NA | ||
| 36907048 | 2023 | IWLTALKFLGKNLGKHLAKQQLSKL{nt:H}{ct:Amid} | LVTX-8 | Amidation | H | Linear | L | None | 25 | Anticancer | 66.7 % Hemolysis at >5 µM | Human | Spider Lycosa Vittata | PBS buffer = α-Helical | NA | ||
| 36907048 | 2023 | IWLTALKFLGKNLGKHLAKQQLSKL{nt:hydrazide = NHNH2}{ct:Acet} | 825 | Acetylation | hydrazide = NHNH2 | Linear | L | None | 25 | Anticancer | 16.7 % Hemolysis at >5 µM | Human | Lvtx-8-Analogs | PBS buffer = α-Helical | Low hemolytic | ||
| 36907048 | 2023 | GFLG-IWLTALKFLGKNLGKHLAKQQLSKL{nt:MTX}{ct:Amid} | 827 | Amidation | MTX | Linear | L | MTX = methotrexate | 29 | Anticancer | 35.8 % Hemolysis at >5 µM | Human | Lvtx-8-Analogs | PBS buffer = α-Helical | NA | ||
| 25626077 | 2015 | FLFKLIPKVIKGLVKAIRK{ct:Amid} | AaeAP1a | Amidation | Free | Linear | L | None | 19 | Antibacterial, Antifungal. Anticancer, Antiproliferative | 100 % Hemolysis at 32 μg/ml | Horse | Aaeap1 Analogues | 31.58% α-Helix | NA | ||
| 25626077 | 2015 | FLFKLIPKAIKGLVKAIRK{ct:Amid} | AaeAP2a | Amidation | Free | Linear | L | None | 19 | Antibacterial, Antifungal. Anticancer, Antiproliferative | 100 % Hemolysis at 64 μg/ml | Horse | Aaeap2 Analogues | 31.58% α-Helix | NA | ||
| 35606468 | 2022 | GLLGKILGAGKKVLCGVSGLC | Nigrocin-PN | Free | Free | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 10 µM | Horse | Pelophylax Nigromaculatus | Random coil | Non-hemolytic | ||
| 35606468 | 2022 | GLLGKILGAGKKVLCGVSGLC | Nigrocin-PN | Free | Free | Linear | L | None | 21 | Antimicrobial, Anticancer | <5 % Hemolysis at 100 µM | Horse | Pelophylax Nigromaculatus | Random coil | Non-hemolytic | ||
| 35606468 | 2022 | GLLGKILGAGKKVLLGVSGLL | Nigrocin-M1 | Free | Free | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 10 µM | Horse | Pelophylax Nigromaculatus | Random coil | Non-hemolytic | ||
| 35606468 | 2022 | GLLGKILGAGKKVLLGVSGLL | Nigrocin-M1 | Free | Free | Linear | L | None | 21 | Antimicrobial, Anticancer | <20 % Hemolysis at 100 µM | Horse | Pelophylax Nigromaculatus | Random coil | Non-hemolytic | ||
| 35606468 | 2022 | GLLGKILGAGKKVL | Nigrocin-M2 | Free | Free | Linear | L | None | 14 | Antimicrobial, Anticancer | 0 % Hemolysis at 10 µM | Horse | Pelophylax Nigromaculatus | Random coil | Non-hemolytic | ||
| 35606468 | 2022 | GLLGKILGAGKKVL | Nigrocin-M2 | Free | Free | Linear | L | None | 14 | Antimicrobial, Anticancer | 0 % Hemolysis at 100 µM | Horse | Pelophylax Nigromaculatus | Random coil | Non-hemolytic | ||
| 36364155 | 2022 | PTECQVGTTCVESS{nt:Amid} | PS14 | Free | Amidation | Linear | L | None | 14 | Anticancer, Anti-inflammatory | 25.45 ± 1 % Hemolysis at 5 μM | Human | Aphanomyces Invadans | NA | NA | ||
| 36364155 | 2022 | PTECQVGTTCVESS{nt:Amid} | PS14 | Free | Amidation | Linear | L | None | 14 | Anticancer, Anti-inflammatory | 39.21 ± 1.5 % Hemolysis at 10 μM | Human | Aphanomyces Invadans | NA | NA | ||
| 36364155 | 2022 | PTECQVGTTCVESS{nt:Amid} | PS14 | Free | Amidation | Linear | L | None | 14 | Anticancer, Anti-inflammatory | 49.10 ± 1.89 % Hemolysis at 15 μM | Human | Aphanomyces Invadans | NA | NA | ||
| 36364155 | 2022 | PTECQVGTTCVESS{nt:Amid} | PS14 | Free | Amidation | Linear | L | None | 14 | Anticancer, Anti-inflammatory | 69 ± 1.3 % Hemolysis at 20 μM | Human | Aphanomyces Invadans | NA | NA | ||
| 36364155 | 2022 | PTECQVGTTCVESS{nt:Amid} | PS14 | Free | Amidation | Linear | L | None | 14 | Anticancer, Anti-inflammatory | 77 ± 2.8 % Hemolysis at 25 μM | Human | Aphanomyces Invadans | NA | NA | ||
| 25561178 | 2015 | {nnr:x}ISQ{d}I{d}IST{d}A{nnr:X}I | Teixobactin | Free | Free | Linear | Mix | x = NmPhe(N-methylated phenylalanine), X = End (Enduracididine) | 11 | Anticancer, Antibacterial | No Hemolysis | Human | Eleftheria Terrae | NA | Non-hemolytic | ||
| 11835991 | 2002 | GIGTKILGGVKTALKGALKELASTYAN{ct:Amid} | Maximin 1 | Amidation | Free | Linear | L | None | 27 | Antibacterial, Antiviral, Antifungal, candidacidal, Spermicidal, Anti-HIV, Hemolytic, Anticancer | Low Hemolysis at 50μg/mL | Rabbit | Chinese Red Belly Toad, Bombina Maxima | Helix | Low hemolytic | ||
| 19254736 | 2009 | FLPAIVGAAAKFLPKIFCAISKKC | Brevinin-1BLa | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer | 50 % Hemolytic at 14µM | Human | Leopard Frog, Lithobates Yavapaiensis, North America | NA | NA | ||
| 19254736 | 2009 | FLPIIAGVAAKVLPKIFCAISKKC | Brevinin-1BLb | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, Hemolytic, Anticancer | Hemolytic | Human | Leopard Frog, Lithobates Yavapaiensis, North America | NA | NA | ||
| 19254736 | 2009 | FLPIIAGIAAKFLPKIFCTISKKC | Brevinin-1BLc | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer | 50 % Hemolytic at 9µM | Human | Leopard Frog, Lithobates Yavapaiensis, North America | NA | NA | ||
| 19254736 | 2009 | FLPVIAGVAANFLPKLFCAISKKC | Brevinin-1Ya | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer | 50 % Hemolytic at 18µM | Human | Leopard Frog, Lithobates Yavapaiensis, North America | NA | NA | ||
| 19254736 | 2009 | FLPIIAGAAAKVVEKIFCAISKKC | Brevinin-1Yc | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer | 50 % Hemolytic at 13µM | Human | Leopard Frog, Lithobates Yavapaiensis, North America | NA | NA | ||
| 21596752 | 2011 | GIPCGESCVFIPCITGAIGCSCKSKVCYRN{cyc:N-C} | Cliotide T1 | Free | Free | Cyclic | L | None | 30 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 7.1µM | Human | Plant Clitoria Ternatea | NA | NA | ||
| 21596752 | 2011 | GLPTCGETCTLGTCYVPDCSCSWPICMKN{cyc:N-C} | Cliotide T3 | Free | Free | Cyclic | L | None | 29 | Hemolytic, Anticancer | 50 % Hemolytic at 13.1µM | Human | Plant Clitoria Ternatea | NA | NA | ||
| 21596752 | 2011 | GIPCGESCVFIPCITAAIGCSCKSKVCYRN{cyc:N-C} | Cliotide T4 | Free | Free | Cyclic | L | None | 30 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 8.4µM | Human | Plant Clitoria Ternatea | NA | NA | ||
| 22467870 | 2012 | GDACGETCFTGICFTAGCSCNPWPTCTRN{cyc:N-C} | ChaC1 (chassatide C1) | Free | Free | Cyclic | L | None | 29 | Hemolytic, Anticancer | Hemolytic | Human | Hybrid Peptide | Bridge | NA | ||
| 22467870 | 2012 | GASCGETCFTGICFTAGCSCNPWPTCTRN{cyc:N-C} | ChaC4 (chassatide C4) | Free | Free | Cyclic | L | None | 29 | Hemolytic, Anticancer | Hemolytic | Human | Plant Chassalia Chartacea (Or Chassalia Curviflora) | Bridge | NA | ||
| 22467870 | 2012 | IPCGESCVWIPCITAIAGCSCKNKVCYT | ChaC7 (chassatide C7) | Free | Free | Linear | L | None | 28 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 11.6µM | Human | Plant Chassalia Chartacea (Or Chassalia Curviflora) | Bridge | NA | ||
| 22467870 | 2012 | AIPCGESCVWIPCISTVIGCSCSNKVCYR | ChaC8 (chassatide C8) | Free | Free | Linear | L | None | 29 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 25.5µM | Human | Plant Chassalia Chartacea (Or Chassalia Curviflora) | Bridge | NA | ||
| 22467870 | 2012 | IPCGESCVWIPCISGMFGCSCKDKVCYS | ChaC11 (chassatide C11) | Free | Free | Linear | L | None | 28 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 13.3µM | Human | Plant Chassalia Chartacea (Or Chassalia Curviflora) | Bridge | NA | ||
| 31328553 | 2021 | SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC{ct:Amid} | Esculentin-2 HYba1 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 15µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 31328553 | 2021 | SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC{ct:Amid} | Esculentin-2 HYba2 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 12µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 31328553 | 2021 | SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC | Esculentin-2 HYba1 | Free | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 10µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 31328553 | 2021 | SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC | Esculentin-2 HYba2 | Free | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 10µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 38611812 | 2024 | FLPLLAGLAASFLPTIFCKISRKC{ct:C-terminus contains a Rana box: one disulfide bond.} | Brevinin-1BW | C-terminus contains a Rana box: one disulfide bond. | Free | Linear | L | None | 24 | Antibacterial, Anti-inflammatory, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer | 50 % Hemolytic at 35.8µg/ml | Sheep | Skin, Pelophylax Nigromaculatus, East Asia | NA | NA | ||
| 39204443 | 2024 | FLSLIPHAISAVSALAKHL | Phylloseptin-TO2 | Free | Free | Linear | L | None | 19 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer | 50 % Hemolytic at 64µM | Horse | Skin Secretion, Super Tiger Leg Monkey Tree Frog, Phyllomedusa Tomopterna, Central America, South America | Helix | NA | ||
| 39204443 | 2024 | FLSLIPKAISAVSALAKHL | PSTO2 7K | Free | Free | Linear | L | None | 19 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer | 50 % Hemolytic at 32-64µM | Horse | Synthetic Peptide | Helix | NA | ||
| 39204443 | 2024 | FLSLIPKAISAVSALAKKL | PSTO2 18K | Free | Free | Linear | L | None | 19 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer | 50 % Hemolytic at 64µM | Horse | Synthetic Peptide | Helix | NA | ||
| 39204443 | 2024 | FLSLIPKAIKAVSALAKKL | PSTO2 SR (Phylloseptin-TO2 analog) | Free | Free | Linear | L | None | 19 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer | 50 % Hemolytic at 64µM | Horse | Synthetic Peptide | Helix | NA | ||
| 39204443 | 2024 | FLSLIPKAIKAVKALAKKL | PSTO2 SR2 (Phylloseptin-TO2 analog) | Free | Free | Linear | L | None | 19 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Anti-sepsis, Hemolytic, Antibiofilm, Anticancer | 50 % Hemolytic at 32µM | Horse | Synthetic Peptide | Helix | NA | ||
| 39345903 | 2024 | FFPIVAGVAAKVLKKIFCTISKKC | Brevinin-1pl (natural AMPs; frog, amphibians, animals; XXU; 1S=S, UCSS1a; BBL) | Free | Free | Linear | L | None | 24 | Antibacterial, Anticancer, Anti-MRSA, Hemolytic | 50 % Hemolytic at 37.64µM | Horse | Skin Secretions, The Northern Leopard Frog, Rana Pipiens, North America | Helix | NA | ||
| 39427973 | 2025 | FLPFLGKLFSGIF{ct:Amid} | Temporin-PMb | Amidation | Free | Linear | L | None | 13 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 32-64µM | Human | Skin Secretion, The Amazon River Frog, Lithobates Palmipes (Ranidae), Brazil, South America | NA | NA | ||
| 32414842 | 2020 | GFPCGESCVYIPCFTAAIGCSCKSKVCYKN | Hyen D | Free | Free | Linear | L | None | 30 | Anticancer, Hemolytic | 50 % Hemolytic at 24.56µM | Human | Hybanthus Enneaspermus | NA | NA | ||
| 17277458 | 2007 | DCCHNTQLPFIYKTCPEGCNL | Cardiotoxin-like basic polypeptide ah (CLBPah) | Free | Free | Linear | L | None | 21 | Anticancer | Hemolytic | Rabbit | Naja Atra (Chinese Cobra) | NA | NA |